Immuno-Oncology Summit | Predict Cancer Therapy Outcomes

Introducing i-Ome^® Cancer

Transform your cancer research with i-Ome Cancer, the largest and most advanced cancer-focused protein microarray on the market.

Profile autoantibodies against 500+ meticulously selected protein antigens, each chosen for their relevance in cancer.
Discover biologically relevant biomarkers with correctly folded proteins, guaranteed by proprietary KREX^® technology
Analyze two isotypes (IgG, IgA, or IgM) in a single, powerful assay.

To learn more about i-Ome Cancer, stop by Sengenics Booth 18.

i-Ome Cancer - Cancer Type Content pie chart - 20240801 - White font

White Paper

Autoantibodies: Next-Generation Biomarkers in Cancer Precision Medicine

Autoantibodies, or antibodies that target self-molecules, can serve as precise and reliable biomarkers in cancer. Get your free white paper to learn how autoantibodies offer valuable insights into cancer mechanisms and therapeutic targets, aiding in early diagnosis, predicting treatment response, and guiding drug development.

Read White Paper

White Paper: Next-Generation Biomarkers in Cancer Precision Medicine

The Sengenics Advantage

Since 90% of antibodies produced by our immune system target three-dimensional protein structures called conformational epitopes, accurate autoantibody screening demands correctly-folded proteins – guaranteed by Sengenics KREX^® technology. Other arrays use protein fragments or improperly folded proteins, leading to missing epitopes, non-specific binding, and high background noise.

Discover why Sengenics excels in immunoproteomics:

Native Protein Structure
Expertly Curated and Comprehensive Library
High Sensitivity
Wide Linear Range
Highly Reproducible
Minimal Sample Volume
Versatile and Scalable
Dual Isotype Analysis
Ready-To-Use and Custom Microarrays

Proprietary KREX technology ensures that only correctly folded proteins are on the array, ensuring biologically relevant results.

KREX^® technology ensures that proteins are correctly folded on Sengenics microarrays for biologically relevant results.

Antibody Biomarkers: Direct Indicators of Disease Status

Profiling humoral antibodies enables the discovery of targetable proteins and pathogenic antibodies, as well as uncovering exploitable protective antibodies to advance precision medicine. Antibodies possess key characteristics of ideal biomarkers, as listed to the right.

Learn More

Manifest Early

Produced early in protective and pathogenic processes

Predictive

Level correlates with process intensity

Abundant

High concentration in minimal sample volume

Stable

Easily transported, stored, and handled

Specific

Highly specific and stable antibody-antigen binding

Accessible

Present in peripheral fluids and tissues

Sengenics, a functional proteomics company, is committed to advancing precision medicine by empowering researchers with biologically relevant and actionable immunoproteomic insights across a broad spectrum of diseases. At the heart of its mission, Sengenics offers advanced, high-throughput tools using proprietary technology to precisely detect autoantibody biomarkers and protein interactions for basic, translational, and clinical research. Its robust tools have been leveraged by top pharmaceutical companies and leading research institutions to enhance disease understanding and streamline the biomarker pipeline.

Design and development by RainCastle Communications.

Immuno-Oncology Summit 2024

Introducing i-Ome^® Cancer

White Paper

Autoantibodies: Next-Generation Biomarkers in Cancer Precision Medicine

The Sengenics Advantage

Antibody Biomarkers: Direct Indicators of Disease Status

Manifest Early

Predictive

Abundant

Stable

Specific

Accessible

Fill in the form to download the publication

Watch the video

Watch the video

Autoantibody-Based Diagnostic Biomarkers: Technological Approaches to Discovery and Validation

Read the Review

Watch the video

Immuno-Oncology Summit 2024

Introducing i-Ome® Cancer

White Paper

Autoantibodies: Next-Generation Biomarkers in Cancer Precision Medicine

The Sengenics Advantage

Antibody Biomarkers: Direct Indicators of Disease Status

Manifest Early

Predictive

Abundant

Stable

Specific

Accessible

Introducing i-Ome^® Cancer